Efficacy and safety of dexmedetomidine combined with tramadol for patient-controlled intravenous analgesia in Chinese surgical patients

A systematic review and meta-analysis

Peng Chen, MD, Fuchao Chen, MD, Jiexin Lei, MD, Benhong Zhou, PhD

Abstract

Background: Patient-controlled intravenous analgesia (PCIA) has been suggested as an effective method of pain relief. There are several randomized controlled trials (RCTs) of dexmedetomidine (DEX) combined with tramadol for PCIA in Chinese surgical patients. The purpose of this study was to perform a systematic review and meta-analysis to evaluate the efficacy and safety of DEX combined with tramadol for PCIA in Chinese surgical patients from current data.

Methods: The RCTs of DEX combined with tramadol for PCIA were gathered from the PubMed, Excerpta Medica Database, Cochrane Library, Cochrane Library, China National Knowledge Infrastructure database, and VIP databases. After data extraction and quality assessment of the included RCTs, RevMan 5.3 software was employed for the meta-analysis of visual analog scale (VAS) scores, Ramsay sedation scores, effective pressure times for PCIA, tramadol consumption, and safety.

Results: Fourteen RCTs were included. Compared with tramadol alone, postoperative intravenous tramadol-DEX combination PCA led to lower VAS scores (weighted mean differences [WMD]12h = 0.14, 95% confidence interval [CI] 0.10 to 0.18; WMD24h = 0.14 to 0.18; CM -0.09 to 0.02; WMD48h = 0.09, 95% CI -0.11 to 0.00; all P < .05), lower Ramsay sedation scores (WMD12h = 0.08, 95% CI 0.07 to 0.09; WMD24h = 0.09, 95% CI -0.11 to 0.00; all P < .05), and less postoperative tramadol consumption (WMD0–24h = -102.59 mg, 95% CI -149.68 to -55.49; WMD0–48h = -152.91 mg, 95% CI -259.93 to -45.89; all P < .05). With regard to safety, there was a significant difference between DEX-tramadol and tramadol for PCIA in terms of the incidence of postoperative nausea and vomiting, dizziness, chills, and restlessness (all P < .05).

Conclusion: According to the domestic evidence, this systematic review and meta-analysis suggests that DEX-tramadol PCIA is superior to tramadol in terms of analgesic efficacy and safety for Chinese surgical patients. However, because of some clear limitations (sample size and heterogeneity), these results should be interpreted with caution. Further large-scale and well-designed studies are needed to summarize and analyze the data to draw a more convincing conclusion.

Abbreviations: ADRs = adverse reactions, AEs = adverse events, DEX = dexmedetomidine, EBM = evidence-based medicine, PCIA = patient-controlled intravenous analgesia, PONV = postoperative nausea and vomiting, RCTs = randomized controlled trials, VAS = visual analog scale.

Keywords: dexmedetomidine, efficacy, meta-analysis, patient-controlled intravenous analgesia, safety, systematic review, tramadol

1. Introduction

Opioids are the most commonly used medications to manage postoperative pain. However, it is difficult for surgical patients to take drugs orally to relieve pain. In contrast, the administration of intravenous analgesics is very appropriate.[1] Patient-controlled intravenous analgesia (PCIA), in which many drugs are mixed in a small container and delivered via a syringe, has been used in clinical practice for many years.[2] Tramadol hydrochloride is a centrally acting synthetic analgesic with opioid and nonopioid actions and has been commonly used in the management of postoperative pain, visceral and cancer-related pain.[3] PCIA with tramadol is a convenient treatment regimen for postoperative pain and is widely used in clinical practice.[4] However, it is always associated with adverse reactions (ADRs), such as nausea and vomiting, which can affect the quality of life of patients and can lead to discomfort and mental consequences.

Dexmedetomidine (DEX) is an effective alpha-2 adrenergic receptor agonist that is mainly used for sedation, anti-anxiety, and analgesia in clinical patients. This drug can reduce opioid requirements and potentiate analgesia without any respiratory
depression during treatment and has been widely administered for the prevention and treatment of postoperative nausea and vomiting (PONV) during PCIA for several decades.\(^5\) Due to the clinical benefits of DEX, the combination use of DEX-tramadol for PCIA is gaining popularity. Recently, several published studies have concentrated on this strategy and compared the analgesic efficacy and safety between DEX combined with tramadol and tramadol alone for PCIA, but the sample sizes were not sufficient, and the results were inconclusive.\(^6\)

Thus, the evidence supporting its use remains controversial and a systematic evaluation of methodologic quality is lacking. This systematic review and meta-analysis was performed to compare the effects of postoperative intravenous DEX-tramadol and tramadol alone for PCIA on the efficacy and safety of analgesia in Chinese surgical patients.

2. Methods

2.1. Data sources and search strategy

PubMed, Excerpta Medica Database, Cochrane Library, China National Knowledge Infrastructure database, Chinese Scientific Journals Full Text Database, Wanfang Data Knowledge Service Platform, and the Chinese Biomedical Literature Service System were searched from January 1997 to January 2019 using the keywords “dexmedetomidine,” “tramadol,” “patient-controlled analgesia,” and “Chinese surgical patients” as well as “clinical trials.” In addition, we also searched the abstracts that contained “dexmedetomidine combined with tramadol for patient-controlled intravenous analgesia in Chinese surgical patients” presented at the European Society for Medical Oncology and major meetings of the American Society of Clinical Oncology. The publication years were from 2004 to 2019. Finally, the references from the Web of Science database were also scanned to ensure that no additional studies were missed.

2.2. Study selection

We included studies meeting the following criteria:

1. randomized clinical trials (RCTs);
2. Chinese adult surgical patients receiving PCIA;
3. trials comparing DEX and tramadol with tramadol for PCIA performed by medical staff;
4. data available for the postoperative pain-related outcomes and adverse events (AEs).

The exclusion criteria were as follows:

1. case series or single-arm trials;
2. nonrandomized trials;
3. DEX used in combination with tramadol for PCIA after surgery rather than for anesthesia intraoperatively;
4. original studies that meet criterion;
5. but lacked information such as visual analog scale (VAS) scores, Ramsay sedation scores, and AEs.

2.3. Data extraction and quality evaluation

We extracted from the included trials the following information: the first author, year of publication, number of patients enrolled in the study, treatment proposal, and types of surgical operation. The outcome variables included the following:

1. VAS scores and Ramsay sedation scores at 6 time points (postoperative hours 4, 6, 8, 12, 24, and 48);
2. tramadol consumption during postoperative hours 0 to 24 and 0 to 48;
3. effective pressure times for PCIA; and
4. the proportion of patients experiencing opioid-related AEs (PONV, dizzy, chills, drowsiness, and bradycardia).

We evaluated the methodological quality of the included studies, according to the following RCT quality evaluation standards of the Cochrane review manual 5.3.0:

1. generation of the random allocation scheme;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data; and
6. selective reporting.

The risk of bias of each study was summarized as “high,” “low” or “unclear.” Any disagreement was settled by discussion or negotiation.

2.4. Statistical analysis

The statistical analysis was performed with Review Manager Version 5.3 software, which was provided by the Cochrane Collaboration, Oxford, UK. The effect size of categorical outcomes was determined by the pooled odds ratio (OR), along with 95% confidence intervals (CIs). The continuous results were calculated by weighted mean differences (WMD) with 95% CI. The between-study heterogeneity was assessed using the Chi-squared test. If \(I^2 < 50\% (P > .1)\), the fixed-effect model was used; if not (\(I^2 > 50\%, P < .1\)), the random effect model was employed, and we attempted to discover the cause of the heterogeneity. Egger test was used to evaluate the presence of publication bias. \(P\)-values less than .05 or .01 were considered significant. All analyses were based on previous published studies, and no ethics approval or patient consent was required.

3. Results

3.1. Search results

A total of 172 documents were obtained through the preliminary examination of the databases. Of those, 21 potential studies were considered eligible after reading the title and abstract. After analyzing the full-text articles, 7 studies that did not meet the inclusion criteria were excluded, and 14 studies\(^7^-^2^0\) were found to be eligible for inclusion according to our criteria and were ultimately included in the meta-analysis. The selection procedure is described in Figure 1, which illustrates how the 14 studies were obtained.

The 14 selected studies, comprising a total of 848 Chinese surgical patients (DEX-tramadol combination group: 425 patients; tramadol monotherapy group: 423 patients), were all RCTs investigating the use of a DEX-tramadol combination compared with tramadol alone for postoperative PCIA. Of the 14 studies, 6 studies\(^7^-^9,13,14,17,18\) combined DEX with tramadol for PCIA up to postoperative hour 24, and the other 8 trials\(^12,15,16,19,20\) were up to hour 48. The dose of analgesics varied among trials, and the main characteristics of the included trials are listed in Table 1.
3.2. Meta-analysis results of effectiveness between DEX-tramadol and tramadol for PCIA in Chinese surgical patients

3.2.1. Meta-analysis of VAS scores. In total, 10 trials\cite{7,8,10–15,19,20} (n=426) were included in the meta-analysis for VAS scores at postoperative hours 4, 6, 8, 12 and 24. With regard to the pain intensity at 12 hours, 24 hours, and 48 hours, the results showed that pain scores in patients receiving PCIA with a DEX-tramadol combination were significantly lower than those in patients receiving tramadol alone. The WMD increased from 0.14 (95% CI: −1.50 to 1.79, \(P=0.004\), \(I^2=98\%\)) at postoperative hour 12 to 0.78 (95% CI: −0.92 to −0.62), \(P<0.01\), \(I^2=92\%\) at postoperative hour 24 and decreased to 0.51 (95% CI: −0.66 to −0.38), \(P<0.01\), \(I^2=94\%\) at postoperative hour 48. The results for the VAS scores of the included trials are listed in Table 2.

3.2.2. Meta-analysis of Ramsay sedation scores. Data reporting the Ramsay sedation scores at postoperative hours 24 and 48 were described in 7 trials\cite{7,8,10,11,17–20} Significant differences in Ramsay sedation scores in patients receiving PCIA with a DEX-tramadol combination compared with patients receiving tramadol alone were found at all time points (WMD = 0.08, 95% CI: −0.14 to −0.02, \(P=0.03\), \(I^2=53\%\); WMD = 0.09, 95% CI: −0.11 to −0.07, \(P<0.01\), \(I^2=40\%\), respectively, Table 2).

3.2.3. Meta-analysis of effective pressure times for PCIA. Data reporting effective pressure times for PCIA were described in 5 trials\cite{8,10,11,14,19} The effective pressure times for PCIA were significantly lower in patients receiving DEX-tramadol combination therapy than in patients receiving tramadol during postoperative hours 0 to 24 and 0 to 48 (WMD = −2.65, 95% CI: −4.52 to −0.79, \(P<0.01\), \(I^2=89\%\); WMD = −5.02, 95% CI: −6.52 to −3.50, \(P<0.01\), \(I^2=98\%\), Table 2).
Table 1
Characteristics of included studies.

| Study                  | Sample, N | Duration of treatment | Pain treatment after surgery (loading dose, PCA system) | Main outcomes |
|------------------------|-----------|-----------------------|--------------------------------------------------------|---------------|
| An et al 2016[7]       | 50        | 24 h                  | T1 g + D200 μg/100 mL PCA                               | 1, 2, 4, 5    |
| Jin et al 2016[8]      | NA        | 48 h                  | T10 mg/kg + D2 μg/kg + A24 mg PCA                       | 1, 2, 3, 4, 5  |
| Li et al 2014[9]       | 46        | 24 h                  | T1 μg/kg + D1 μg/kg PCA                                | 1, 5          |
| Li et al 2015[10]      | 100       | 48 h                  | T0.7 mg/kg + D2 μg/kg PCA                              | 1, 2, 3, 4, 5  |
| Liu et al 2015[11]     | 30        | 48 h                  | T15 mg/kg + D4 μg/kg + G3 mg PCA                       | 1, 2, 3, 5    |
| Wang et al 2016[12]    | 50        | 24 h                  | T1 μg/kg + D100 μg/100 mL PCA                           | 1, 3, 4, 5    |
| Wang et al 2016[13]    | 20        | 24 h                  | T1 μg/kg + A10 mg/100 mL PCA                            | 1             |
| Wang et al 2016[14]    | 30        | 48 h                  | T100 mg + A10 mg/100 mL PCA                            | 4, 5          |
| Wang et al 2016[15]    | 20        | 24 h                  | T100 mg + D100 μg/100 mL PCA                           | 4, 5          |
| Wang et al 2016[16]    | 46        | 48 h                  | T100 mg + A10 mg/100 mL PCA                            | 1, 3, 4, 5    |
| Xu et al 2012[17]      | NA        | 48 h                  | T1 g + D200 μg/100 mL PCA                              | 1, 4, 5       |
| Yang et al 2013[18]    | 30        | 24 h                  | T400 mg + D100 μg/100 mL PCA                           | 1, 2, 4, 5    |
| Yuan et al 2016[19]    | 60        | 24 h                  | T600 mg + T100 μg + F100 μg/100 mL PCA                  | 2, 4, 5       |
| Zhao et al 2016[20]    | 30        | 48 h                  | T100 mg + A10 mg/100 mL PCA                            | 1, 3, 4, 5    |
| Zhou et al 2015[21]    | 20        | 48 h                  | T15 mg/kg + D1 μg/kg + A8 mg PCA                        | 1, 2, 5       |

1 Visual analog scale (VAS) scores; 2 Ramsay scores; 3 Effective pressure times for PCA; 4 Tramadol consumption; 5 Adverse reaction rate.

A = ondansetron, D = dexmedetomidine, F = flurbiprofenacetil, G = granisetron, PCA = patient-controlled analgesia, T = tramadol.

3.2.4. Meta-analysis of tramadol consumption. The analysis of the postoperative opioid requirements included 8 trials [7,10,14,16–19]. A significant decrease in tramadol consumption was observed in patients receiving the combination of DEX-tramadol for PCA during postoperative hours 0 to 24 (WMD0–24h = −102.59 mg, 95% CI: −149.68 to −55.49, P < .01, I² = 99%) and postoperative hours 0 to 48 (WMD0–48h = −152.91 mg, 95% CI: −259.93 to −45.88, P < .005, I² = 96%, Table 2) when compared to the patients receiving tramadol alone.

Table 2
Meta-analysis results of effectiveness between DEX-tramadol and tramadol for PCA in Chinese surgical patients.

| Outcomes                  | Trails (n) | Participants (n) | P value | Statistical method | Results of meta-analysis |
|---------------------------|------------|------------------|---------|--------------------|--------------------------|
| VAS scores                |            |                  |         |                    | Estimated benefit (95% CI) | P value     |
| At 4 h                    |            |                  |         | Random             | WMD = 0.14 [−1.50, 1.79] | .09         |
| At 6 h                    |            |                  |         | Random             | WMD = 0.52 [−0.90, 1.14] | .12         |
| At 8 h                    |            |                  |         | Random             | WMD = −0.74 [−1.06, −0.42] | .07         |
| At 12 h                   |            |                  |         | Random             | WMD = −0.76 [−1.22, −0.36] | .0004       |
| At 24 h                   |            |                  |         | Random             | WMD = −0.78 [−0.92, −0.62] | < .01       |
| At 48 h                   |            |                  |         | Random             | WMD = −0.51 [−0.66, −0.38] | < .01       |
| Ramsay scores             |            |                  |         |                    | Estimated benefit (95% CI) | P value     |
| At 4 h                    |            |                  |         | Random             | WMD = 0.04 [−0.50, 0.60] | .82         |
| At 6 h                    |            |                  |         | Random             | WMD = −0.72 [−2.06, 0.69] | .28         |
| At 8 h                    |            |                  |         | Random             | WMD = 0.10 [−0.45, 0.62] | .74         |
| At 12 h                   |            |                  |         | Random             | WMD = −0.32 [−0.80, 0.11] | .17         |
| At 24 h                   |            |                  |         | Random             | WMD = −0.08 [−0.14, −0.02] | .03         |
| At 48 h                   |            |                  |         | Random             | WMD = −0.09 [−0.11, −0.07] | < .01       |
| Effective pressure times for PCA | 24 h |                  |         | Fixed              | WMD = −2.65 [−4.52, −0.79] | < .01       |
| At 24 h                   |            |                  |         | Random             | WMD = −5.02 [−6.52, −3.50] | < .01       |
| At 48 h                   |            |                  |         | Random             | WMD = −5.02 [−6.52, −3.50] | < .01       |

CI = confidence interval, D = dexmedetomidine, PCA = patient-controlled intravenous analgesia, T = tramadol, VAS = visual analog scale, WMD = weighted mean differences.
of double-blinding, and 11 trials \[7,8,10\] clearly reported allocation concealment. The funnel plot shows a certain asymmetry (Fig. 2), indicating that there is some degree of publication bias. However, the number of studies included was only ten, and the funnel plots may not be very reliable. Egger test revealed that there was no significant difference in the ORs of AEs in our study \( (P = .32) \).

### 3.3. Meta-analysis results of safety between DEX-tramadol and tramadol for PCIA in Chinese surgical patients

For the safety analysis, we selected several of the most frequent AEs. All the meta-analysis results regarding AEs are listed in Table 3. Data reporting AEs were described in 14 trials, \[7\] – \[20\]. There were lower incidences of PONV (OR = 0.26, 95% CI: 0.16–0.42, \( P < .01 \), \( I^2 = 97\% \)), dizziness (OR = 0.29, 95% CI: 0.14–0.61, \( P < .01 \), \( I^2 = 46\% \)), chills (OR = 0.18, 95% CI: 0.06–0.52, \( P = .0002 \), \( I^2 = 94\% \)), and restlessness (OR = 0.03, 95% CI: 0.02–0.08, \( P < .01 \), \( I^2 = 10\% \)) in patients receiving PCIA with DEX-tramadol combination than in patients receiving tramadol alone. The total ADR rate in patients treated with DEX-tramadol was significantly lower than that in patients treated with tramadol alone (OR = 0.21, 95% CI: 0.15–0.27, \( P < .01 \), \( I^2 = 35\% \)). There was no report of other AEs, including rash, bradycardia, diarrhea, or respiratory depression, in either group.

### 3.4. Risk of bias in included studies

The risk of bias assessment of the included studies is shown in Table 4. Six trials, \[7\] – \[13\], \[14\] – \[19\] detailed the methods of randomization, 10 trials, \[7\] – \[9\], \[11\] – \[14\], \[16\] – \[20\] detailed the methods of double-blinding, and 11 trials, \[7\] – \[8\], \[10\] – \[16\] – \[19\] clearly reported allocation concealment. The funnel plot shows a certain asymmetry (Fig. 2), indicating that there is some degree of publication bias. However, the number of studies included was only ten, and the funnel plots may not be very reliable. Egger test revealed that there was no significant difference in the ORs of AEs in our study \( (P = .32) \).

### 4. Discussion

Critically ill hospitalized patients are often in need of many drugs for postoperative pain management. \[21\] Over the years, opioid drugs such as fentanyl, tramadol, and morphine have been the preferred drugs for postoperative pain, occupying an important position in postoperative pain management. \[22\] The opioid analgesic effect is considerable, but opioids cause several ADRs, such as nausea, vomiting, dizziness, and drowsiness, which are very detrimental to treatment and recovery during postoperative analgesia. \[14\], \[15\] Postoperative multimodal analgesia (MA) pain management with different types of postoperative analgesics may provide powerful pain relief with reduced side effects for patients who have undergone operations. \[16\] – \[23\] Recent studies have revealed that the analgesic effect of \( \alpha \)-2 adrenergic receptor agonist DEX, which has a higher affinity for the \( \alpha \)-2 adrenergic receptor than the \( \alpha \)-1 adrenergic receptor at a ratio of 1620:1, maybe a new treatment approach for MA treatment. \[24\]

To the best of our knowledge, this is the first meta-analysis evaluating the efficacy and safety of DEX combined with tramadol for PCIA in Chinese surgical patients. \[25\] In the current meta-analysis including data from 848 patients, we found that the DEX-tramadol combination PCIA strategy led to lower
postoperative pain intensity, lower postoperative opioid consumption, and lower incidences of PONV and dizziness compared to tramadol alone. These findings of this meta-analysis suggest that the combined use of DEX-tramadol for PCIA provided superior pain relief than tramadol alone.

Previous studies have concentrated on the use of DEX for preoperative or intraoperative analgesia.[3,24] The current meta-analysis revealed that the postoperative administration of the combination of DEX and tramadol induced analgesic and tramadol-sparing effects. In addition, published meta-analyses have shown that the use of the DEX-tramadol combination for PCIA in patients resulted in significantly greater pain relief compared with opioids alone. In this meta-analysis, patient-reported pain intensity was found to be less in the DEX-tramadol group at 24 and 48 hours compared to the tramadol group. Because of the negative WMD in VAS scores and Ramsay sedation scores between the DEX-tramadol and tramadol groups, it can be deduced that DEX combined with tramadol for PCIA is likely to be more effective at treating pain compared with conventional analgesia.[26] These improved analgesic effects provided by DEX may result from modulation of the release of catecholamines, synergistic analgesic interactions with the opioid tramadol, and attenuation of the stress response to surgery and anesthesia.[27]

DEX is a potent and highly selective agonist and is approved by the US Food and Drug Administration for the postoperative sedation of patients requiring mechanical ventilation for less than 24 hours. Unlike the usual tranquilizers, DEX acts mainly on the central nervous system in the locus coeruleus to exert the same calming effect as natural sleep. However, no evidence has been found in our meta-analysis to show this DEX-induced excessive sedation during postoperative PCA. There may be a number of reasons for this:

1. PCA permits patients to titrate intravenous opioids, which may play an important role in the prevention of additional sedative effects;
2. if higher doses of PCA are needed to provide more effective pain relief during the analgesic period, the pain could counteract the excessive sedation; and
3. the sedation levels may decrease along with the reduction in the cumulative dose of opioids for PCA.

The results of our meta-analysis also showed that there were significantly lower postoperative opioid consumption levels at 24 hours (WMD of 102.59 mg, tramadol consumption) and 48 hours (WMD of 152.91 mg, tramadol consumption) in patients administered the tramadol-DEX combination, and they needed less postoperative rescue analgesia. In addition, our meta-analysis demonstrated that the addition of DEX to tramadol for PCIA might significantly decrease the incidences of PONV, dizziness, chills, and restlessness. There are 2 possible explanations:

1. the low dose of tramadol in the DEX-tramadol combination reduced the risk of side effects associated with opioid drugs and
2. the antiemetic characteristics of DEX, due to the decrease in norepinephrine activity and sedative effect, may explain the lower incidence of PONV.[28,29]

However, there are no reports to date about the details of perioperative antiemetic prophylaxis.

There are several limitations in our analysis. First, because only 14 RCTs were included, the number of studies is small, and the sample size of patients in our study was also insufficient, potentially making the conclusions less convincing. Second, the difference in PCA dose regimens increased the bias in the calculations of tramadol consumption. Third, pain perception is individual and is impacted by participants’ tolerance, the progression of labor, human influences (eg, psychological influence from doctors or nurses), analgesic doses, and other factors. Thus, the pain score by itself may not reflect pain relief efficacy.[30] Fourth, it is difficult for us to correlate our data with the dose delays/interruptions or discontinuations secondary to AEs in the analysis. Fifth, we observed significant heterogeneities in analytical indicators such as VAS scores, Ramsay scores, effective pressure times for PCIA and tramadol consumption; therefore, these findings must be assessed with caution. Sixth, because the studies included in this analysis were from China, the
results need confirmation in a wider range of ethnicities. Furthermore, there may have been publication bias; it could not be completely excluded based on the funnel plot. Finally, there is a lack of data on the long-term outcomes of the effect of DEX combined with tramadol for PCA in the treatment of chronic pain. Therefore, it is necessary to carry out more large-scale and high-quality RCTs to summarize and analyze the data to confirm this conclusion.

Furthermore, a frequent problem is that mixing 2 or more injections together in infusion solutions induces physical changes, and the chemical degradation of ingredients could cause precipitation/crystallization and therefore reduce the analgesic efficacy.[31] Many clinical studies have evaluated the efficacy of DEX as an adjunct to tramadol PCA for pain relief, but little or no information is available about the physical or chemical changes in the analgesic mixtures.[32] Therefore, clinicians should evaluate the compatibility and stability of binary admixtures of DEX and tramadol in the future to improve the safety and efficacy of these drugs.

5. Conclusion

In summary, our systemic review and meta-analysis initially demonstrated that the analgesic effects of DEX-tramadol for PCA in Chinese surgical patients; we found that compared with tramadol alone, the DEX-tramadol combination resulted in superior analgesia effect, significant opioid sparing effects, and fewer AEs. Postoperative DEX administration may play an important role in multimodal treatment regimens for postoperative pain. Opioid-DEX combination is a safe and effective strategy for postoperative intravenous PCA. However, all the clinical trials involved had small sample sizes and no blinding, and their results may be unreliable. We urgently hope that large-scale, high-quality, double-blinded, and multicenter RCTs will be performed in the future to further confirm the efficacy and safety of PCA with the DEX-tramadol combination.

Author contributions

Conceptualization: Peng Chen.
Data curation: Peng Chen.
Formal analysis: Peng Chen.
Investigation: Peng Chen.
Methodology: Peng Chen.
Project administration: Peng Chen, Zhou ben hong.
Resources: Peng Chen.
Software: Peng Chen, Fuchao Chen, Jiexin Lei.
Supervision: Peng Chen.
Validation: Peng Chen.
Visualization: Peng Chen.
Writing – original draft: Peng Chen.
Writing – review and editing: Peng Chen.
Zhou Ben Hong orcid: 0000-0002-6129-0182.

References

[1] Zivna D, Sehonova P, Pihalova L, et al. Effect of salicylic acid on early life stages of common carp (Cyprinus carpio). Environ Toxicol Phar 2015;40:319–25.
[2] Velde MVD, Devro S, Rooffhoof F. Editorial remifentanil PCA for labour analgesia: a world of caution. Acta Anaesthesiol Belg 2016;67:149–50.
[3] Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol 2015;53:545–50.
[4] Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome; a review. Pain Physician 2015;18:395–400.
[5] Shukla U, Prabhakar T, Malhotra K, et al. Intrapertoneal bupivacaine alone or with dexametomidine or tramadol for post-operative analgesia following laparoscopic cholecystectomy: a comparative evaluation. Indian J Anaesth 2015;59:234–9.
[6] Snotra RS, Viscusi ER, Ding L, et al. Meta-analysis of the efficacy of the fentanyl iontophoretic transdermal system versus intravenous patient-controlled analgesia in postoperative pain management. Expert Opin Pharmacother 2015;16:1607–13.
[7] An XH, Xu T, Wang W, et al. Efficacy of dexametomidine combined with tramadol for patient-controlled intravenous analgesia after cesarean section. J Tongji Univ (Med Sci) 2016;37:80–3.
[8] Jin CJ, Xu LH, Zhou J. Effect of dexametomidine combined with tramadol on analgesia after simple nephrectomy. Pract Pharmac Clin Remed 2016;19:1306–9.
[9] Li QZ, Yang SL, Wang XE, et al. Dexametomidine combined with tramadol preventing remifentanil-induced hyperalgesia. Chin Gen Phram 2014;17:3514–7.
[10] Li XL, Shen HF, He JX, et al. The application of the combination of dexametomidine and tramadol for patients after abdominal surgery. Chin J Clin Rational Drug Use 2015;8:49–51.
[11] Liu QY, Ji Y, Wang YJ, et al. The effects of dexametomidine on the postoperative analgesia with tramadol. Acta Nanjing Med Univ (Nat Sci) 2015;35:1313–6.
[12] Wang QL. Analysis of the efficacy of low dose dexametomidine combined with tramadol in patients with controlled intravenous analgesia after radical mastectomy. Chin J Prescption Drug 2015;13:556–6.
[13] Wang XF, Wang JQ, Tao Q, et al. The effect of the dexametomidine combined with tramadol on preventing post-anesthetic hyperalgesia induced by remifentanil. J Bengbu Med Coll 2016;41:211–4.
[14] Wang Y, Zhu YZ, Liu G. The effects of dexametomidine combined tramadol on the use of anesthetic drugs in the total hip arthroplasty. Hebei Med 2016;22:415–8.
[15] Wang ZF, Liu DY. Dexametomidine combined with tramadol used in thirty cases of patients with nasal endoscopic surgery. Chin Pharm 2013;2:98–9.
[16] Xu XH, Song WT. The clinical efficacy of low dose of dexametomidine combined with tramadol in patients with controlled intravenous analgesia after radical. Guangdong Med 2012;33:4670–2.
[17] Yang HR, Hong H. Effect of dexametomidine combined with tramadol for patient-controlled intravenous analgesia for elderly patients with essential hypertension. Pract Pharmac Clin Remed 2013;16:116–8.
[18] Yuan AI, Li Jian Gang. The effect of dexametomidine combined with tramadol for postoperative analgesia in elderly patients with hypertension. World Latest Med Inform 2016;16:112–8.
[19] Zhao BZ, Wang QY, Liu L. The application of dextrometomidine and tramadol in patients with controlled intravenous analgesia. Med front 2016;6:142–3.
[20] Zhou YW, Heng J, Yang T, et al. Observation of the effect of operation analgesia with tramadol combined of dexametomidine. Chongqing Med 2015;7:660–1.
[21] Abdolkarimi B, Zarefaz S, Golestanl ME, et al. Comparison effect of intravenous ketamine with pethidine for analgesia and sedation during bone marrow procedures in oncologic children: a randomized, double-blind, crossover trial. Int J Hematol Oncol Stem Cell Res 2016;10:206–11.
[22] Tsuruta R, Fujita M. Comparison of clinical practice guidelines for the management of pain, agitation, and delirium in critically ill adult patients. Acute Med Surg 2018;5:207–12.
[23] Na W, Zhou H, Song X, et al. Comparison of oxycodeone and sulentanil for patient-controlled intravenous analgesia after laparoscopic radical gastrectomy: a randomized double-blind clinical trial. Anesth Essays Res 2016;10:557–60.
[24] Peng K, Liu HY, Wu SR, et al. Effects of combining dexametomidine and opioids for postoperative intravenous patient-controlled analgesia: a systematic review and meta-analysis. Chin J Pain 2015;31:1097–104.
[25] Sarridou DG, Chalmouki G, Braoudaki M, et al. Intravenous parecoxib and continuous femoral block for postoperative analgesia after total knee arthroplasty. A randomized, double-blind, prospective trial. Pain Physician 2015;18:267–76.
[26] Akça B, Arslan A, Yilbaş AA, et al. Comparison of the effects of patient controlled analgesia (PCA) using dexmedetomidine and propofol during septoplasty operations: a randomized clinical trial. Springerplus 2016;5:1–9.

[27] Kim NY, Kwon TD, Bai SJ, et al. Effects of dexmedetomidine in combination with fentanyl-based intravenous patient-controlled analgesia on pain attenuation after open gastrectomy in comparison with conventional thoracic epidural and fentanyl-based intravenous patient-controlled analgesia. Int J Med Sci 2017;14:951–60.

[28] Choi YY, Park JS, Park SY, et al. Can intravenous patient-controlled analgesia be omitted in patients undergoing laparoscopic surgery for colorectal cancer? Ann of Surg Treat Res 2015;88:86–91.

[29] Kim DK, Yoon SH, Ji YK, et al. Comparison of the effects of sufentanil and fentanyl intravenous patient controlled analgesia after lumbar fusion. J Korean Neurosurg Soc 2017;60:54–9.

[30] Biccard BM, Goga S, De BJ. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials. Anaesthesia 2010;63:4–14.

[31] Gu J, Qin W, Chen F, et al. Long-term stability of tramadol and ketamine solutions for patient-controlled analgesia delivery. Med Sci Monitor 2015;21:2528–34.

[32] Fang B, Wang L, Gu J, et al. Physicochemical stability of ternary admixtures of butorphanol, ketamine, and droperidol in polyolefin bags for patient-controlled analgesia use. Drug Des Dev Ther 2016;10:3873–8.